SEARCH

SEARCH BY CITATION

References

  • Boni, A., Cogdill, A.P., Dang, P., Udayakumar, D., Njauw, C.N., Sloss, C.M. et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 52135219.
  • Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949954.
  • Dummer, R., Robert, C., Chapman, P.B., Sosman, J.A., Middleton, M., Bastholt, L., Kemsley, K., Cantarini, M.V., Morris, C., and Kirkwood, J.M. (2008). AZD6244 (ARRY-a428896) versus temozolomide (TMZ) in patients with advanced melanoma: an open-label, randomized, multicenter, phase II study. J. Clin. Oncol. 26: Abstract 9033.
  • Eisen, T., Ahmad, T., Flaherty, K.T., Gore, M., Kaye, S., Marais, R. et al. (2006). Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581586.
  • Flaherty, K.T., Schiller, J., Schuchter, L.M., Liu, G., Tuveson, D.A., Redlinger, M. et al. (2008). A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res. 14, 48364842.
  • Flaherty, K., Puzanov, I., Sosman, J., Kim, K., Ribas, A., McArthur, G., Lee, R.J., Grippo, J.F., Nolop, K., and Chapman, P. (2009). Phase I study of PLX4032: Proof of concept for V600EBRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27, 15s.
  • Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809819.
  • Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S. et al. (2010). PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23, 190200.
  • Halilovic, E., She, Q.B., Ye, Q., Pagliarini, R., Sellers, W.R., Solit, D.B. et al. (2010). PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling. Cancer Res. 70, 68046814.
  • Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B.J., Anderson, D.J., Alvarado, R. et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431435.
  • Heidorn, S.J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209221.
  • Hodi, F.S., O’ Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B. et al. (2010). Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N. Engl. J. Med. 363, 711723.
  • Joseph, E.W., Pratilas, C.A., Poulikakos, P.I., Tadi, M., Wang, W., Taylor, B.S. et al. (2010). The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. U S A 107, 1490314908.
  • King, A.J., Patrick, D.R., Batorsky, R.S., Ho, M.L., Do, H.T., Zhang, S.Y. et al. (2006). Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66, 1110011105.
  • Krasilnikov, M., Ivanov, V.N., Dong, J., and Ronai, Z. (2003). ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22, 40924101.
  • Meier, F., Nesbit, M., Hsu, M.Y., Martin, B., Van Belle, P., Elder, D.E. et al. (2000). Human melanoma progression in skin reconstructs : biological significance of bFGF. Am. J. Pathol. 156, 193200.
  • Meier, F., Busch, S., Lasithiotakis, K., Kulms, D., Garbe, C., Maczey, E. et al. (2007). Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br. J. Dermatol. 156, 12041213.
  • Montagut, C., Sharma, S.V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L.E. et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 48534861.
  • Nathanson, K.L. (2010). Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. Biochem. Pharmacol. 80, 755761.
  • Park, E.S., Rabinovsky, R., Carey, M., Hennessy, B.T., Agarwal, R., Liu, W. et al. (2010). Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9, 257267.
  • Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., and Rosen, N. (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427430.
  • Roesch, A., Fukunaga-Kalabis, M., Schmidt, E.C., Zabierowski, S.E., Brafford, P.A., Vultur, A. et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583594.
  • Shepherd, C., Puzanov, I., and Sosman, J.A. (2010). B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep 12, 146152.
  • Smalley, K., and Sondak, V. (2010). Melanoma – an unlikely poster child for personalized cancer therapy. N. Engl. J. Med. 363, 876878.
  • Tsai, J., Lee, J.T., Wang, W., Zhang, J., Cho, H., Mamo, S. et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U S A 105, 30413046.
  • Villanueva, J., Cipolla, A.K., Kong, J., Neri, M.K., Nathanson, K.L., Lee, J.T., and Herlyn, M. (2009). A kinase switch underlies acquired resistance to BRAF inhibitors. Pigment Cell Melanoma Res. 22, 903.
  • Wee, S., Jagani, Z., Xiang, K.X., Loo, A., Dorsch, M., Yao, Y.M. et al. (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 42864293.
  • Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R. et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 55185527.